Lexagene Holdings (Lexagene Holdings) Retained Earnings : $-50.34 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lexagene Holdings's retained earnings for the quarter that ended in Nov. 2022 was $-50.34 Mil.

Lexagene Holdings's quarterly retained earnings declined from May. 2022 ($-47.00 Mil) to Aug. 2022 ($-48.32 Mil) and declined from Aug. 2022 ($-48.32 Mil) to Nov. 2022 ($-50.34 Mil).

Lexagene Holdings's annual retained earnings declined from Feb. 2020 ($-24.37 Mil) to Feb. 2021 ($-34.27 Mil) and declined from Feb. 2021 ($-34.27 Mil) to Feb. 2022 ($-44.89 Mil).

Lexagene Holdings Retained Earnings Historical Data

The historical data trend for Lexagene Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Retained Earnings Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Retained Earnings

Get a 7-Day Free Trial

-8.55

-16.88

-24.37

-34.27

-44.89

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Retained Earnings	Get a 7-Day Free Trial															-42.51	-44.89	-47.00	-48.32	-50.34

Lexagene Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Lexagene Holdings (OTCPK:LXXGQ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.